Optimize Meds for Peripheral Artery Disease

You'll hear debate about how to manage stable peripheral artery disease (PAD)...now that rivaroxaban (Xarelto) is approved for this use.

Think of managing PAD as similar to coronary artery disease...both are due to plaque buildup.

We know PAD patients have a high risk of complications...such as CV events or limb amputation. Plus they may develop symptoms...claudication or pain that reduces walking distance and quality of life.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals